NEW YORK, Aug. 31, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024. So What: If you purchased Outset Medical securities during the Class P ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Outset Medical securities between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Per ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Outset Medical, Inc. ("Outset Medical" or the "Company") (NYSE: OM) securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the ...

ATLANTA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ: OM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications appr ...

文章核心观点 - 公司的主要产品Tablo系列设备被用于连续性肾脏替代治疗,这并非FDA批准的适应症之一 [1] - 公司可能需要提交额外的510(k)申请以获得Tablo产品的新适应症批准,这存在重大风险 [1] - 公司缺乏足够的销售团队和流程来执行Tablo销售的快速增长 [1] - 上述因素将对公司的收入增长产生不利影响 [1] 根据相关目录分别进行总结 公司业务和产品 - 公司主要产品为Tablo系列设备,用于透析护理,包括Tablo血液透析系统和TabloCart [1] - 公司的Tablo产品被用于连续性肾脏替代治疗,这并非FDA批准的适应症之一 [1] 财务表现 - 公司2024年第二季度财务业绩大幅低于预期,全年收入指引下调390百万美元 [2] - 公司需要采取措施改善执行力,包括销售团队和流程的重组,无法实现之前预测的TabloCart销售增长 [2] 股价表现 - 公司股价在2024年8月8日下跌68.53%,收于每股1.07美元,成交量异常激增 [2]

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. What if I purchased Outset Medical securities? If you purchased securities and suffered ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...

LOS ANGELES, Aug. 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Outset released its second quarter 2024 financial results on August 7, 2024. The ...

Outset Medical (NASDAQ:OM) stock is taking a beating on Thursday after the medical technology company announced earnings results for the second quarter of the year. The Outset Medical earnings report starts with an adjusted EPS of -47 cents. That's worse than the -43 cents per share that Wall Street was expecting. That's despite it being better than the -69 cents per share from the same period of the year prior. On top of that, Outset Medical posted revenue of $27.39 million during the quarter. That's anoth ...

财务数据和关键指标变化 - 第二季度收入为27.4亿美元,较第一季度下降3%,主要由于控制台销售低于预期 [27] - 产品收入为19.2亿美元,其中控制台收入为7.2亿美元,较第一季度下降22% [28] - 耗材收入增长近8%,同比增长超过25%至12.1亿美元 [28] - 服务及其他收入增长5%至8.2亿美元,同比增长22% [29] - 非GAAP毛利率为37.3%,较第一季度提高6个百分点,同比提高14个百分点 [31] - 产品毛利率创纪录达44.8%,服务及其他毛利率为19.8% [31][32] - 非GAAP净亏损为2470万美元,较上一季度和去年同期分别下降16%和27% [34] 各条业务线数据和关键指标变化 - 治疗销售同比增长25% [9] - 控制台平均销售价格同比增长超过8% [9] - 控制台安装基数同比增长18% [9] - 使用Tablo的急性护理设施数量同比增长16% [9] 各个市场数据和关键指标变化 - 急性和亚急性市场:新增近30家客户,并在两家最大的医疗系统中继续推进战略内部化 [24] - 家庭市场:保持行业领先的保留率,90天保留率维持在90%,累计保留率约10% [26] - 多家中型透析机构和护理机构扩大使用Tablo [26] 公司战略和发展方向及行业竞争 - 公司正从早期采用者转向主流企业采用者,这需要改变销售方式、销售对象和销售流程 [13][14][15] - 需要重塑销售团队,引入具有不同背景和技能的人才,建立更具纪律性的销售流程 [16][17][18] - 这一转型需要几个季度的时间,预计下半年收入与上半年相当,全年收入约110亿美元 [19][43] - 公司仍对长期增长前景保持乐观,一旦转型完成将恢复强劲、持续的收入增长 [46] 管理层对经营环境和未来前景的评论 - 公司拥有强大的差异化产品,在急性和家庭市场都有广泛的客户需求 [21][48] - 公司的经营模式和毛利率持续扩张都证明了其商业模式的力量 [49] - 公司致力于实现盈利,这是一个可盈利的业务,因为有可预测的经常性收入、良好的毛利率和内在的操作杠杆 [50] 其他重要信息 - 公司现金和现金等价物、短期投资及受限现金为1.982亿美元 [42] - 预计2024年非GAAP毛利率将在低到中30%区间 [44] - 预计2024年非GAAP营业费用约为1.2亿美元,低于之前指引 [45] 问答环节重要的提问和回答 问题1 **Marie Thibault 提问** 公司正在进行的人员变动是否意味着销售团队规模会缩小,以及新引进的人才是否已就位并开始销售 [59][60][61][62] **Leslie Trigg 回答** 公司已经在领导层和资本销售团队中引进了具有不同背景和成功经验的人才,未来会在整个组织中复制这种人才结构 [60][61][62] 销售团队规模整体不会大幅缩小,重点是调整团队的构成和技能结构 [61] 公司的现场服务和支持团队规模和构成不会发生变化,他们是公司增长经常性收入的关键 [62] 问题2 **Rick Wise 提问** 公司之前预期Tableau Cart的回归会加速订单,但实际情况并非如此,是否存在其他因素导致销售周期延长 [64][65][66][67] **Nabeel Ahmed 回答** 公司之前确实认为Tableau Cart的回归会推动一些被延迟的交易,但事实上还存在其他因素导致销售周期延长,主要是客户群体从早期采用者转向更加谨慎的主流企业客户 [65][66][67] 这需要公司改变销售方式和销售团队,以更好地满足这些客户的需求 [67] 问题3 **Suraj Kalia 提问** 公司为何会出现业绩下滑,是否存在内部预测问题或价格敏感性增加,以及大单合同是否已签订 [101][102][103][104][105][106][107] **Leslie Trigg 回答** 公司预计转型过程会带来一定程度的disruption,加上大单合同的销售周期较长,这是导致收入下滑的主要原因 [103][104][105] 价格敏感性并非问题,因为Tablo在急性和亚急性市场能带来50%-70%的成本节约 [106] 公司管线中的大单合同并未全部签订,而是处于销售流程的不同阶段,公司正在努力提高预测和执行能力 [107][108][109]